查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863570

單細胞多組體學市場：2025-2032年全球預測（依產品、技術、應用、最終使用者和工作流程分類）

Single-Cell Multi-Omics Market by Product, Technology, Application, End User, Workflow - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，單細胞多組體學市場將成長至 74.7 億美元，複合年成長率為 11.27%。

關鍵市場統計數據
基準年 2024 31.8億美元
預計年份：2025年 35.4億美元
預測年份 2032 74.7億美元
複合年成長率 (%) 11.27%

本書權威地概述了單細胞多組體學如何發展成為一個多學科平台，並重塑了研究重點和轉化研究流程。

單細胞多組體學已從一個小眾研究領域發展成為現代生命科學的基石，重塑了研究人員揭示細胞異質性和生物系統的方式。近年來，調查方法的進步提高了基因組、轉錄組、蛋白質組和空間層面的解析度，從而能夠對組織內、發育過程中以及疾病狀態下的細胞進行整合觀察。因此，這一系列技術能夠支持更廣泛的實驗目標，從生物標記發現和機制研究到標靶識別和藥物最佳化，使其成為學術界和工業界不可或缺的工具。

同時，技術應用趨勢也在轉變。早期採用者專注於概念驗證實驗和基準調查方法，而目前採用者則更注重通量、可重複性和能夠提供可操作洞見的端到端工作流程。這種成熟趨勢推動了對儀器、耗材、樣本和樣品製備套件以及利用人工智慧和先進生物資訊技術的複雜數據分析解決方案的投資。因此，相關人員不僅需要關注儀器性能，還必須考慮供應商生態系統、資料互通性和監管要求。

從發現到應用的轉變帶來了新的營運複雜性和策略決策。各機構必須權衡高解析度資料的需求與通量、成本和下游分析能力。此外，濕實驗室科學家、計算生物學家和臨床團隊之間的多學科合作至關重要。本文為深入探討技術轉折點、監管和貿易阻力、特定領域的機會、區域差異以及為希望利用單細胞多體學技術進步的領導者提供的策略建議奠定了基礎。

這是一個關鍵的技術和生態系統轉折點，它將加速生命科學工作流程中的多模態整合、吞吐量和分析複雜性。

單細胞多組體學領域正經歷著一場變革性的轉變，這主要得益於儀器技術、化學和計算分析的融合。儀器供應商正致力於開發高通量、整合的分析方法，以同時捕捉DNA、RNA、蛋白質和空間訊息，從而降低實驗總成本並縮短獲得有效結果所需的時間。同時，試劑和樣品製備化學技術的進步也提高了捕獲效率並降低了技術變異性，從而增強了不同研究間結果的一致性和可重複性。

在計算方面，機器學習技術與可擴展生物資訊學流程的融合，大大提升了解讀大規模、複雜、多模態資料的能力。這些工具不僅增強了訊號提取和批次效應校正，還支援預測建模和細胞狀態軌跡估計，從而為目標選擇和實驗設計提供資訊。因此，數據分析正從事後考慮轉變為工作流程規劃的核心組成部分，這需要對人員和基礎設施進行投入。

此外，生態系統正朝向服務導向型發展。儀器製造商擴大將儀器與數據分析服務和持續支援捆綁銷售，以降低非計算型終端用戶的使用門檻。同時，儀器製造商、試劑供應商和軟體開發商之間的合作正在打造垂直整合的解決方案，從而簡化實驗流程。這些變化正在塑造技術提供者和服務機構之間新的競爭格局，並加速單細胞研究成果向臨床應用的轉化。

2025年關稅調整對生命科學領域高價值設備和耗材籌資策略、供應鏈韌性和供應商選擇的影響

影響跨境貿易的政策趨勢正為2025年的採購、供應鏈設計和資本規劃帶來實際考量。關稅調整及相關貿易措施有可能增加設備和特殊試劑的到岸成本，迫使實驗室和採購團隊重新評估供應商選擇、庫存策略和總擁有成本（TCO）。為此，各機構普遍優先考慮在地採購，實現供應商多元化，並重新談判服務契約，以降低價格波動風險並保障計劃進度。

除了直接的成本影響外，關稅還會影響定序儀、質譜儀和流式細胞儀等高價值設備的供貨和前置作業時間。前置作業時間延長會波及研發專案的運作，可能導致關鍵實驗和下游開發里程碑的延誤。因此，策略性負責人越來越重視地緣政治風險和進口關稅，並將這些因素納入其長期設備更新周期和資本支出核准中，同時尋求租賃安排和本地維護夥伴關係關係，以確保設備的連續性。

最後，貿易措施將重塑供應商之間的競爭格局。擁有分散式製造地或區域組裝中心的公司在保護客戶免受關稅波動影響方面具有優勢，而依賴單一國際供應鏈的公司則可能面臨價格壓力，必須自行承擔或轉嫁這些壓力。對終端使用者而言，2025年關稅的累積效應凸顯了合約彈性、情境規劃以及與供應商建立合作關係的重要性。

實用的細分綜合分析揭示了設備、化學、計算平台和最終用戶需求交叉影響產品開發和購買行為的領域。

細緻的市場區隔架構突顯了單細胞多組體學生態系統中值得關注的投資與創新領域。按產品類型分類，市場涵蓋耗材和試劑、儀器以及服務。耗材和試劑包括套件和用於穩定樣品製備的單一試劑。儀器則涵蓋了資料收集的硬體基礎：流式細胞儀、質譜儀和定序儀。服務包括數據分析、支援和維護，以確保運行的連續性和分析的嚴謹性。

從技術角度來看，單細胞基因組學、蛋白質組學、轉錄組學和空間體學之間的差異凸顯了它們各自不同的技術要求和價值提案。單細胞基因體學又細分為諸如scATAC-seq和scDNA-seq等方法，分別用於研究染色質可及性和基因組變異。單細胞蛋白質體學包括無標定蛋白質體學方法和質譜流式細胞儀，後者能夠實現大規模蛋白質定量。單細胞轉錄組學可分為基於液滴和基於微孔板的工作流程，以平衡通量和靈敏度。空間體學整合了成像質譜和空間轉錄組學，用於原位繪製分子特徵圖。

應用領域的細分揭示了科學和商業性需求集中的領域。生物標記發現涵蓋診斷和預後靶點，疾病研究著重於神經病學和腫瘤學等領域，藥物發現和開發則包括先導化合物最佳化和標靶識別。所有這些都需要專門的實驗設計和分析流程。將最終用戶分為學術和研究機構（進一步細分為政府實驗室和大學）、臨床診斷實驗室（醫院實驗室和獨立實驗室）以及製藥和生物技術公司（從生物技術公司到大型製藥公司），有助於確定採購優先事項、合規要求和服務預期。工作流程細分凸顯了資料分析、樣品製備和樣本製備的重要性。數據分析本身分為人工智慧/機器學習解決方案和傳統生物資訊學工具，而樣品製備包括條碼試劑套件和cDNA合成試劑。樣本製備涵蓋從細胞分離到細胞分選技術，這些技術構成了下游數據品質的基礎。

綜合考慮這些細分層，可以揭示瓶頸出現在哪裡，價值累積在哪裡，以及策略夥伴關係和能力建設將在哪些方面產生最大影響，從而指導產品開發重點，並指南供應商和服務供應商建立滿足端到端工作流程需求的捆綁解決方案。

從區域觀點看全球生命科學中心在推動策略重點的採納促進因素、基礎設施成熟度和合作模式

單細胞多組體學的區域趨勢反映了世界各地不同的法規結構、研究重點和商業基礎設施。在美洲，蓬勃發展的轉化研究活動以及生物技術和製藥公司的高度集中，推動了對整合工作流程和先進分析服務的需求，這些服務專注於臨床應用和治療創新。為了將實驗室發現轉化為臨床應用，研究機構通常與產業夥伴密切合作，這更凸顯了對可擴展、可重複的方法和全面支援服務的需求。

歐洲、中東和非洲地區呈現出多元化的格局，擁有強大的學術研究基礎，以及多樣化的法規環境和資金籌措舉措。在一些歐洲市場，公共部門對生命科學的投資以及合作聯盟的建立，推動了對開放標準和多機構合作的需求，凸顯了互通性和統一通訊協定的重要性。同時，該地區的新興經濟體正致力於能力建設，並推動在地化採用經濟高效的工作流程，以彌合基礎設施和專業知識方面的差距。

亞太地區正經歷快速的自動化應用，這主要得益於不斷成長的研發投入、蓬勃發展的生物技術產業以及在地化生產和分析能力的舉措。該地區匯聚了許多高通量學術研究中心和快速成長的生物技術公司，從而推動了對自動化平台、可擴展試劑供應和雲端數據分析解決方案的需求。跨境合作和區域夥伴關係也促進了這個充滿活力的環境，在這樣的環境中，在地化的服務模式和對監管法規的理解對於市場准入和持續成長至關重要。

供應商之間的競爭和夥伴關係動態決定了整合型企業、服務主導模式的採用以及客戶價值的持續成長。

單細胞多組體學生態系統中的主要企業在儀器、試劑和分析方面佔據互補地位，建構了相互關聯的價值鏈，從而影響創新的軌跡。儀器製造商持續在通量、靈敏度和多模態競爭。服務供應商和分析公司透過連接實驗執行和高級計算解讀而日益受到重視，使那些缺乏深厚內部生物資訊學專業知識的機構能夠最大限度地發揮多模態資料集的價值。

競爭格局正在發生變化，夥伴關係和平台生態系統的重要性日益凸顯。提供整合儀器、檢驗試劑、雲端分析等綜合解決方案的公司，能夠降低終端用戶門檻，加速技術普及。同時，專注於高靈敏度蛋白質體學或空間轉錄組學等細分領域的專業公司，則提供關鍵創新技術，支援廣泛的工作流程。這些專業供應商與平台公司之間的策略合作，往往能夠打造出滿足特定應用需求的整合解決方案，例如腫瘤學中的生物標記發現或神經病學中的單細胞分析。

此外，投資於使用者培訓、可重複性研究和社群參與的公司更有可能培養長期的客戶忠誠度。因此，兼顧產品創新、卓越服務和生態系統夥伴關係的企業策略，最有利於確保學術、臨床和商業終端用戶的持續參與。

為確保工作流程彈性、分析能力和協作途徑，從而實現持續的科學影響，各組織應制定以行動為導向的策略重點。

產業和研究領導者必須採取實際行動，才能在有效管理營運複雜性和成本風險的同時，充分發揮單細胞多體學的策略優勢。首先，他們應優先投資於端到端的工作流程，將樣品製備、文庫建構、儀器操作和分析等環節連接起來，從而減少故障點，並加快獲得洞見的速度。這意味著選擇合作夥伴不僅要考慮組件效能，還要考慮其提供檢驗、可互通的解決方案以及持續支援的能力。

第二，建構計算生物學和資料管治的內部能力。隨著資料集規模和複雜性的成長，能夠開發出穩健的流程、標準化的元資料操作和解釋框架的機構將從多模態實驗中獲得更大的價值。培訓跨職能團隊，使其了解濕實驗室的限制和建模方面的考量，將有助於改進實驗設計和提高實驗的可重複性。第三，將供應鏈風險評估納入採購計劃，並考慮區域採購、供應商多元化和靈活的合約安排等策略，以降低關稅和物流中斷的影響。

最後，應推行風險共用、加速創新的合作模式。公私合營、方法標準化聯盟以及外部資料共用協定能夠降低複雜應用領域的進入門檻，並建立促進跨研究比較的社群標準。透過將投資重點與轉化目標結合，各機構可以將單細胞多組體學從一項研究能力轉變為一項策略性資產，從而支持長期的科學和商業性目標。

透明、多方面的研究途徑整合了專家訪談、技術文獻綜述和通訊協定檢驗，以支持實際結論。

該研究結合了與關鍵專家的面對面訪談、對同行評審文獻的系統性回顧，以及對產品、技術、應用、最終用戶和工作流程等維度的結構化評估。與實驗室主任、採購人員、計算科學家和高級技術主管的對話是了解實驗和轉化環境中的操作實踐、應用促進因素和未滿足需求的資訊來源。這些定性見解輔以方法論文獻和供應商技術規範的分析，以確保性能特徵和工作流程相容性的準確性。

為確保研究的嚴謹性，本研究將訪談檢驗與已記錄的產品特性進行交叉驗證，並透過獨立的第三方評估和社群基準資料對技術能力聲明進行三角驗證。分析方法強調可重複性，記錄了影響最終用戶體驗的通訊協定差異、數據處理選擇和常見故障模式。在整個過程中，研究始終避免對定價或市場規模做出任意假設，而是將重點放在技術能力、營運影響以及相關人員的策略考量上。

最後，在評估採購和實施風險時，也考慮了區域法規和供應鏈因素。調查方法旨在確保透明度和可重複性，使讀者能夠清晰地追溯資訊來源與本報告結論之間的聯繫。

對技術整合、營運規範和協作模式如何將單細胞洞察轉化為應用優勢進行策略性綜合分析。

單細胞多組體學正處於一個關鍵的轉折點，其方法學的成熟度與生物醫學研發的策略需求交匯融合。高性能儀器、精密化學和先進分析技術的整合，使得我們能夠更精確地了解細胞狀態和交互作用，從而直接影響生物標記的發現、疾病研究和藥物研發。然而，要充分發揮這一潛力，需要的不僅是技術的應用；還需要在工作流程、運算能力和穩健的籌資策略進行協同投資。

在各個領域和地區，那些將技術嚴謹性與營運規範相結合的組織將取得最大成功。這包括採用標準化通訊協定、投資資料管治以及建立能夠提供端到端解決方案的夥伴關係。此外，透過在地化策略和靈活的合約結構來應對地緣政治和貿易壓力，對於維持業務連續性和控制總體擁有成本至關重要。最終，單細胞多組體學的策略價值不僅取決於其提供的洞見深度，還取決於其加速轉化成果以及為那些將其巧妙地整合到研發和臨床工作流程中的組織創造永續競爭優勢的能力。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合空間轉錄組學和蛋白​​質組學進行腫瘤異質性的高級分析
  • 一個基於人工智慧的平台，用於全面整合和解讀單細胞多體學數據
  • 用於可擴展單細胞蛋白質體學工作流程的高通量微流體自動化技術
  • 利用雲端基礎的協作流程加速大規模單細胞多體學學研究
  • 單細胞表觀基因分析技術的進步有助於闡明調控機制
  • 多模態成像質譜流式細胞儀在單細胞免疫分析應用的興起
  • 用於個人化醫療的整合式單細胞多體學檢測的商業化
  • 單細胞多組體學技術在免疫腫瘤生物標記開發研究的應用日益廣泛

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：單細胞多組體學市場（依產品分類）

  • 耗材和試劑
    • 套件
    • 試劑
  • 裝置
    • 流式細胞儀
    • 質譜儀
    • 序列器
  • 服務
    • 數據分析服務
    • 支援與維護

9. 按技術分類的單細胞多組體學市場

  • 單細胞基因體學
    • scATAC-seq
    • scDNA-seq
  • 單細胞蛋白質體學
    • 無標定蛋白質體學
    • 質譜流式細胞儀
  • 單細胞轉錄組學
    • 液滴基底
    • 底板
  • 空間體學
    • 成像質譜
    • 空間轉錄組學

第10章 單細胞多組體學市場（依應用分類）

  • 生物標記發現
    • 診斷生物標記
    • 預後生物標記
  • 疾病研究
    • 神經病學
    • 腫瘤學
  • 藥物發現與開發
    • 先導藥物最適化
    • 目標識別

第11章 單細胞體學市場（依最終用戶分類）

  • 學術和研究機構
    • 政府研究機構
    • 大學
  • 臨床診斷實驗室
    • 醫院檢查室
    • 獨立研究機構
  • 製藥和生物技術公司
    • 生技公司
    • 大型製藥企業

第12章：單細胞多組體學市場（依工作流程分類）

  • 數據分析
    • 人工智慧和機器學習解決方案
    • 生物資訊學工具
  • 樣品製備
    • 條碼套件
    • cDNA合成
  • 樣品製備
    • 細胞分離
    • 細胞分選

第13章：單細胞多組體學市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 單細胞體學市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國單細胞體學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • 10x Genomics, Inc.
    • Illumina, Inc.
    • Bio-Rad Laboratories, Inc.
    • Becton, Dickinson and Company
    • Standard BioTools Inc.
    • NanoString Technologies, Inc.
    • Takara Bio Inc.
    • Mission Bio, Inc.
    • IsoPlexis Corporation
    • Resolve Biosciences Ltd.
Product Code: MRR-7C31448F0BAB

The Single-Cell Multi-Omics Market is projected to grow by USD 7.47 billion at a CAGR of 11.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.18 billion
Estimated Year [2025] USD 3.54 billion
Forecast Year [2032] USD 7.47 billion
CAGR (%) 11.27%

An authoritative overview of how single-cell multi-omics has evolved into a cross-disciplinary platform reshaping research priorities and translational pipelines

Single-cell multi-omics has moved from a niche research curiosity to a cornerstone of modern life sciences, reshaping how researchers interrogate cellular heterogeneity and biological systems. Recent methodological advances have increased resolution across genomic, transcriptomic, proteomic, and spatial layers, enabling integrated views of cells within tissues, developmental processes, and disease states. As a result, the technology suite now supports a broader set of experimental goals-from biomarker discovery and mechanistic studies to target identification and drug optimization-making it an indispensable tool for both academia and industry.

At the same time, adoption dynamics are shifting. Early adopters focused on proof-of-concept experiments and methodological benchmarking, whereas current adopters prioritize throughput, reproducibility, and end-to-end workflows that deliver actionable insights. This maturation has spurred investments in instruments, consumables, sample and library preparation kits, and sophisticated data analysis solutions that leverage AI and advanced bioinformatics. Consequently, stakeholders must navigate not only instrument performance but also vendor ecosystems, data interoperability, and regulatory expectations.

Transitioning from discovery to translational applications introduces new operational complexities and strategic decisions. Organizations must balance the need for high-resolution data with throughput, cost, and downstream analytical capacity. Moreover, cross-disciplinary collaboration between wet-lab scientists, computational biologists, and clinical teams has become essential. This introduction sets the stage for a deeper examination of technological inflection points, regulatory and trade headwinds, segmentation-specific opportunities, regional nuance, and strategic recommendations for leaders seeking to capitalize on single-cell multi-omics advancements.

Critical technological and ecosystem inflection points that are accelerating multimodal integration, throughput, and analytic sophistication across life science workflows

The landscape of single-cell multi-omics is undergoing transformative shifts driven by convergence across instrumentation, chemistry, and computational analytics. Instrument vendors are pursuing higher throughput and integrative modalities that allow simultaneous capture of DNA, RNA, proteins, and spatial context, thereby reducing aggregate experimental costs and accelerating time to insight. Parallel advances in reagents and library preparation chemistry have improved capture efficiency and reduced technical variability, enabling more consistent cross-study comparisons and reproducibility.

On the computational side, the integration of machine learning techniques and scalable bioinformatics pipelines has unlocked the capacity to interpret complex multimodal data at scale. These tools are not only enhancing signal extraction and batch-effect correction but are also enabling predictive modeling and cell-state trajectory inference that inform target selection and experimental design. As a result, data analysis is transitioning from an afterthought to a core element of workflow planning, demanding investments in both personnel and infrastructure.

Additionally, the ecosystem is becoming more service-oriented. Providers increasingly bundle instruments with data analysis services and ongoing support to reduce barriers to adoption among non-computational end users. In parallel, partnerships between instrument manufacturers, reagent suppliers, and software developers are creating vertically integrated offerings that streamline experimental workflows. Taken together, these shifts are accelerating the translation of single-cell insights into clinically relevant applications while creating new competitive dynamics among technology providers and service organizations.

How 2025 tariff shifts are reshaping procurement strategies, supply chain resilience, and vendor selection for high-value instruments and consumables in life sciences

Policy developments affecting cross-border trade have introduced practical considerations for procurement, supply chain design, and capital planning in 2025. Tariff adjustments and related trade measures can increase landed costs for instruments and specialized reagents, prompting laboratories and procurement teams to reassess supplier selection, inventory strategies, and total cost of ownership. In response, organizations often prioritize local sourcing where feasible, diversify supplier bases, or renegotiate service contracts to mitigate price exposure and protect project timelines.

Beyond direct cost impacts, tariffs can influence product availability and lead times for high-value equipment such as sequencers, mass spectrometers, and flow cytometers. Extended lead times have operational repercussions for research programs, potentially delaying critical experiments and downstream development milestones. Consequently, strategic buyers are increasingly factoring geopolitical risk and import duties into long-range equipment replacement cycles and capital expenditure approvals, as well as exploring leasing and local maintenance partnerships to maintain continuity.

Finally, trade measures reshape competitive dynamics among vendors. Firms with decentralized manufacturing footprints or regional assembly centers are better positioned to shield customers from tariff volatility, while companies reliant on single-source international supply chains may face pricing pressure that they must either absorb or pass on. For end users, the cumulative effect of tariffs in 2025 underscores the importance of contract flexibility, scenario planning, and collaborative vendor relationships to sustain research momentum and protect innovation timelines.

A practical segmentation synthesis revealing where instruments, chemistries, computational platforms, and end-user needs converge to shape product development and purchasing behavior

A nuanced segmentation framework provides clarity on where investments and innovation are concentrated across the single-cell multi-omics ecosystem. By product, the market spans consumables and reagents, instruments, and services; consumables and reagents encompass both kits and individual reagents that are critical for consistent sample and library preparation, while instruments cover flow cytometers, mass spectrometers, and sequencers that form the hardware backbone for data acquisition, and services include data analysis and support and maintenance offerings that ensure operational continuity and analytical rigor.

From a technology perspective, distinctions between single-cell genomics, proteomics, transcriptomics, and spatial multi-omics highlight differing technical requirements and value propositions. Single-cell genomics subdivides into modalities such as scATAC-seq and scDNA-seq, each addressing chromatin accessibility and genomic variation respectively; single-cell proteomics includes label-free proteomic approaches and mass cytometry that enable quantitative protein measurement at scale; single-cell transcriptomics differentiates between droplet-based and plate-based workflows that balance throughput and sensitivity; spatial multi-omics integrates imaging mass spectrometry and spatial transcriptomics to map molecular features in situ.

Application segmentation reveals where scientific and commercial demand concentrates. Biomarker discovery spans diagnostic and prognostic targets, disease research centers on areas like neurology and oncology, and drug discovery and development covers lead optimization and target identification, all of which require tailored experimental designs and analytic pipelines. End-user distinctions among academic and research institutes-further described by government labs and universities-clinical diagnostics laboratories-differentiated into hospital labs and independent labs-and pharma and biotech entities-ranging from biotech firms to large pharma-shape purchasing priorities, compliance needs, and service expectations. Workflow segmentation underscores the growing importance of data analysis, library preparation, and sample preparation; data analysis itself bifurcates into AI and ML solutions versus conventional bioinformatics tools, library preparation includes barcoding kits and cDNA synthesis reagents, and sample preparation spans cell isolation and cell sorting techniques that are foundational to downstream data quality.

Together, these segmentation layers illuminate where bottlenecks emerge, where value accrues, and where strategic partnerships or capability building can deliver the greatest return. They also guide product development priorities and inform how vendors and service providers craft bundled solutions to address end-to-end workflow needs.

A regionally informed perspective on adoption drivers, infrastructure maturity, and collaboration models shaping strategic priorities across global life science hubs

Regional dynamics in single-cell multi-omics reflect varying regulatory frameworks, research priorities, and commercial infrastructures across the globe. In the Americas, robust translational research activity and a dense concentration of biotech and pharma companies create a high demand for integrated workflows and advanced analytical services, with an emphasis on clinical translation and therapeutic innovation. Research institutions often collaborate closely with industry partners to move discoveries from bench to clinic, amplifying the need for scalable, reproducible methods and comprehensive support services.

Europe, Middle East & Africa present a heterogeneous landscape where strong academic research hubs coexist with diverse regulatory environments and funding models. In several European markets, public investment in life sciences and collaborative consortia fosters an appetite for open standards and multi-center studies, which accentuates the importance of interoperability and harmonized protocols. Meanwhile, emerging economies within the region are focusing on capacity-building initiatives and local adoption of cost-effective workflows to bridge gaps in infrastructure and expertise.

Asia-Pacific demonstrates rapid adoption driven by expanding research investments, a growing biotechnology industry, and initiatives to localize manufacturing and analytic capabilities. The region's mix of high-throughput academic centers and rapidly scaling biotech firms accelerates demand for automated platforms, scalable reagent supplies, and cloud-enabled data analysis solutions. Cross-border collaborations and regional partnerships are also contributing to a dynamic environment where localized service models and regulatory familiarity are increasingly important for market entry and sustained growth.

Competitive positioning and partnership dynamics among vendors that determine which firms drive integration, service-led adoption, and sustained customer value

Key companies shaping the single-cell multi-omics ecosystem occupy complementary positions across instruments, reagents, and analytics, creating interconnected value chains that influence innovation trajectories. Instrument manufacturers continue to compete on throughput, sensitivity, and multimodal integration, while reagent suppliers differentiate through chemistry improvements that enhance capture efficiency and reduce technical noise. Service providers and analytics firms are gaining prominence by bridging experimental execution with advanced computational interpretation, thereby enabling organizations without deep in-house bioinformatics expertise to realize the full value of multimodal datasets.

Competitive dynamics increasingly favor partnerships and platform ecosystems. Companies that offer comprehensive bundles-combining instruments, validated reagents, cloud-enabled analytics, and support-reduce friction for end users and accelerate adoption. At the same time, specialist firms that focus on niche capabilities, such as high-sensitivity proteomics or spatial transcriptomics, provide critical innovations that feed into broader workflows. Strategic collaborations between these specialist providers and platform companies often yield integrated solutions that address specific application needs, such as biomarker discovery in oncology or single-cell profiling in neurology.

Moreover, companies that invest in user training, reproducibility studies, and community engagement are more likely to cultivate long-term customer loyalty. As a result, corporate strategies that balance product innovation with service excellence and ecosystem partnerships are best positioned to capture sustained engagement from academic, clinical, and commercial end users.

Action-oriented strategic priorities for organizations to secure workflow resilience, analytic capability, and collaborative pathways for sustainable scientific impact

Leaders in industry and research institutions must act deliberately to capture the strategic benefits of single-cell multi-omics while controlling operational complexity and cost exposure. First, prioritize investments in end-to-end workflows that link sample preparation, library construction, instrumentation, and analytics to reduce failure points and accelerate time to insight. This means selecting partners based not only on component performance but also on their ability to deliver validated, interoperable solutions and ongoing support.

Second, build internal capabilities in computational biology and data governance. As datasets grow in volume and complexity, organizations that develop robust pipelines, standardized metadata practices, and interpretive frameworks will extract greater value from multimodal experiments. Training cross-functional teams to understand both wet-lab constraints and modeling considerations will enhance experimental design and reproducibility. Third, incorporate supply chain risk assessments into procurement planning and consider strategies such as regional sourcing, vendor diversification, and flexible contracting to mitigate tariff and logistics disruptions.

Finally, pursue collaborative models that share risk and accelerate innovation. Public-private partnerships, consortia for method standardization, and external data-sharing agreements can lower barriers to entry for complex applications and produce community standards that facilitate cross-study comparisons. By aligning investment priorities with translational goals, organizations can transform single-cell multi-omics from a research capability into a strategic asset that supports long-term scientific and commercial objectives.

A transparent, multi-source research approach combining expert interviews, technical literature review, and protocol validation to underpin actionable conclusions

This research synthesizes primary expert interviews, a systematic review of peer-reviewed literature, and a structured assessment of product, technology, application, end-user, and workflow dimensions. Primary inputs include discussions with laboratory directors, procurement leaders, computational scientists, and senior technology executives to capture operational realities, adoption drivers, and unmet needs across experimental and translational settings. These qualitative insights were complemented by an analysis of methodological literature and vendor technical specifications to ensure accuracy on performance attributes and workflow compatibility.

To ensure rigor, the study applied cross-validation between interview insights and documented product characteristics, and it triangulated claims about technology capabilities with independent third-party evaluations and community benchmarks. The analytic approach emphasized reproducibility by documenting protocol variants, data processing choices, and common failure modes that influence end-user experiences. Throughout, attention was paid to avoiding proprietary assumptions about pricing or market sizing; the focus remained on technology capabilities, operational implications, and strategic considerations for stakeholders.

Finally, sensitivity to regional regulatory and supply chain factors informed the assessment of procurement and deployment risks. The methodology is designed to be transparent and reproducible, providing readers with clear traceability between source inputs and the conclusions drawn in this report.

A strategic synthesis highlighting how technical integration, operational discipline, and collaborative models convert single-cell insights into translational advantage

Single-cell multi-omics stands at an inflection point where methodological maturity converges with strategic necessity for biomedical research and development. The integration of high-performance instruments, refined chemistries, and advanced analytics is enabling more precise interrogation of cellular states and interactions, with direct implications for biomarker discovery, disease research, and drug development. However, realizing this potential requires more than technology acquisition; it demands coordinated investments in workflows, computational talent, and resilient procurement strategies.

Looking across segments and regions, the most successful adopters will be those that couple technical rigor with operational discipline: implementing standardized protocols, investing in data governance, and engaging in partnerships that deliver end-to-end solutions. Additionally, responsiveness to geopolitical and trade-related pressures through localized strategies and flexible contracting will be essential to preserve continuity and manage total cost of ownership. Ultimately, the strategic value of single-cell multi-omics will be measured not only by the depth of insight it provides but by its ability to accelerate translational outcomes and create sustainable competitive advantage for organizations that integrate it thoughtfully into their R&D and clinical workflows.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of spatial transcriptomics with proteogenomics for enhanced tumor heterogeneity analysis
  • 5.2. AI-driven platforms for comprehensive single-cell multi-omics data integration and interpretation
  • 5.3. High-throughput microfluidics automation enabling scalable single-cell proteogenomics workflows
  • 5.4. Cloud-based collaborative pipelines accelerating large-scale single-cell multi-omics research
  • 5.5. Advancements in single-cell epigenomic profiling techniques for uncovering regulatory mechanisms
  • 5.6. Emergence of multimodal imaging mass cytometry in single-cell immune profiling applications
  • 5.7. Commercialization of integrated single-cell multi-omics assays for personalized medicine discovery
  • 5.8. Expansion of single-cell multi-omics adoption in immuno-oncology biomarker development studies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single-Cell Multi-Omics Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Kits
    • 8.1.2. Reagents
  • 8.2. Instruments
    • 8.2.1. Flow Cytometers
    • 8.2.2. Mass Spectrometers
    • 8.2.3. Sequencers
  • 8.3. Services
    • 8.3.1. Data Analysis Services
    • 8.3.2. Support & Maintenance

9. Single-Cell Multi-Omics Market, by Technology

  • 9.1. Single-cell Genomics
    • 9.1.1. scATAC-seq
    • 9.1.2. scDNA-seq
  • 9.2. Single-cell Proteomics
    • 9.2.1. Label-free Proteomics
    • 9.2.2. Mass Cytometry
  • 9.3. Single-cell Transcriptomics
    • 9.3.1. Droplet-based
    • 9.3.2. Plate-based
  • 9.4. Spatial Multi-omics
    • 9.4.1. Imaging Mass Spectrometry
    • 9.4.2. Spatial Transcriptomics

10. Single-Cell Multi-Omics Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Diagnostic Biomarkers
    • 10.1.2. Prognostic Biomarkers
  • 10.2. Disease Research
    • 10.2.1. Neurology
    • 10.2.2. Oncology
  • 10.3. Drug Discovery & Development
    • 10.3.1. Lead Optimization
    • 10.3.2. Target Identification

11. Single-Cell Multi-Omics Market, by End User

  • 11.1. Academic & Research Institute
    • 11.1.1. Government Labs
    • 11.1.2. Universities
  • 11.2. Clinical Diagnostics Laboratories
    • 11.2.1. Hospital Labs
    • 11.2.2. Independent Labs
  • 11.3. Pharma & Biotech
    • 11.3.1. Biotech Firms
    • 11.3.2. Large Pharma

12. Single-Cell Multi-Omics Market, by Workflow

  • 12.1. Data Analysis
    • 12.1.1. AI & ML Solutions
    • 12.1.2. Bioinformatics Tools
  • 12.2. Library Preparation
    • 12.2.1. Barcoding Kits
    • 12.2.2. cDNA Synthesis
  • 12.3. Sample Preparation
    • 12.3.1. Cell Isolation
    • 12.3.2. Cell Sorting

13. Single-Cell Multi-Omics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Single-Cell Multi-Omics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Single-Cell Multi-Omics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. 10x Genomics, Inc.
    • 16.3.2. Illumina, Inc.
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. Becton, Dickinson and Company
    • 16.3.5. Standard BioTools Inc.
    • 16.3.6. NanoString Technologies, Inc.
    • 16.3.7. Takara Bio Inc.
    • 16.3.8. Mission Bio, Inc.
    • 16.3.9. IsoPlexis Corporation
    • 16.3.10. Resolve Biosciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SINGLE-CELL MULTI-OMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SINGLE-CELL MULTI-OMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SINGLE-CELL MULTI-OMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL SI